Bessemer India.
The quiet cash-returner: $683M distributed on $774M committed (2006-2024, leaked) with $1.6bn still marked, a clean staged exit of Medi Assist, Urban Company OFS at 14.4x, now leading Sarvam AI's record Series B on a 'sovereign AI stack' thesis.
GW GP Score
Bessemer India is the anti-drama franchise: two decades, nine India IPOs, a leaked LP dataset showing it has nearly returned its entire committed capital with a $1.6bn residual book still marked, and the honest caveat in the same leak, that IRR lags because the wins compound slowly. The 2025-26 shift is the interesting part: a $350M Fund II (59% step-up), senior AI/cyber hires, and a growth-sized lead in Sarvam AI's $234M+ Series B at $1.5bn, a deliberate departure from its early-stage lane to own the sovereign-AI thesis.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
The important signal is not the latest round; it is whether the firm can keep converting marks into distributions.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Sarvam Series B final size and formal lead designation ($234M first close of ~$300M; press conflicting).
Perfios IPO (~$500M at ~$2bn target): the book's biggest pending realisation.
The Sarvam cheque is a stage-and-size departure: growth pricing in frontier AI is exactly where its early-stage discipline never had to operate.
Computed from current dossier sources; analyst override pending.
Documented distributions, a clean staged-exit playbook, and the cohort's most consequential AI cheque. Positive outlook: the Sarvam and Perfios events give it two near-term re-rating catalysts.
Sarvam + Perfios (>26%) anchor; NephroPlus/UC listed; PharmEasy scar
$683M returned + Medi Assist ~₹1,158 Cr staged exit + UC 14.4x: real, documented cash
Sovereign-AI anchor position via Sarvam; fintech-infra depth
Fund II $350M closed Mar 2025 at +59% step-up; deploying lead cheques fast
Gupta/Puri continuity + senior additions; no departures found
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
Perfios liquidity clears with credible OFS/block-sale evidence.
Perfios IPO (~$500M at ~$2bn target): the book's biggest pending realisation.
Sarvam Series B final size and formal lead designation ($234M first close of ~$300M; press conflicting).
The leak did Bessemer a favour: near-1x returned with $1.6bn still marked is a profile most India managers claim and can't show. Underwrite Fund II on whether the 2021 vintage finds its breakout, and treat the Sarvam position as a call option you're paying growth prices for.
The Sarvam cheque is a stage-and-size departure: growth pricing in frontier AI is exactly where its early-stage discipline never had to operate.
Sarvam Series B final size and formal lead designation ($234M first close of ~$300M; press conflicting).
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution1 positive catalyst(s), 0 pressure catalyst(s); top driver: India PE-VC value down 5% YoY in H1 CY2026.
The broad private-capital backdrop is selective rather than euphoric; fundraising and mark support now need firm-specific proof.
Score pressureRaises the bar for weak-DPI managers and stale flagship vehicles; rewards funds with fresh closes or visible exits.
Separate broad PE-VC softness from venture AI strength before changing sector-positioning scores.
The funds
$570M India-dedicated ($220M Fund I + $350M Fund II) + global-fund history across 3 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| India Fund II | 2025Recovery / IPO window | $350M | Early | Closed Mar 2025: 59% step-up over Fund I; 3-4 year deployment |
| India Fund I | 2021Peak frenzy | $220M | Early | Boldfit, MoveInSync, Shopdeck, Zopper vintage; 'no breakout yet' per leak (mid-2024) |
| Global-fund India history | 2006-2020Foundation era | $774M committed | Multi | Source of the Medi Assist / Urban Company / Swiggy positions |
Closest booksProsus Ventures (3 shared) · Trifecta Capital (2 shared) · Accel India (2 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Latest vehicle closed inside the current exit/repricing window.
Next liquidityPerfios · Swiggy
4 visible exit events since Jul 2024.
Latest vehicle closed inside the current exit/repricing window.
8 up / 1 flat / 1 down tracked signals.
No senior departure flagged in key people.
8 up / 1 flat / 1 down
4 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangPharmEasy: names with negative 12-month mark or momentum signals in the reconstructed book.
Exit-led repricing; entry discipline decisive
Cycle-top entry marks; the vintage still being digested
Pre-unicorn pricing; discovery-cost entries
Holds >26%; IPO prep ~$500M at ~$2bn; FY25 profit ₹104 Cr
Claimed as portfolio IPO; absent from OFS list: residual position unclear (U)
At least one cited source is dated 2026.
4 visible events tracked.
12 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 2 · +2
Peer median 2 · +0
Peer median 74 · +10
Peer median 62 · +9
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
The dossier is current and has near-term liquidity or fund events that can change the view quickly.
Current · At least one cited source is dated 2026.
Sarvam Series B final size and formal lead designation ($234M first close of ~$300M; press conflicting).
Refresh after each filing, listing, OFS, first close, final close or partner announcement.
Perfios IPO (~$500M at ~$2bn target): the book's biggest pending realisation.
Perfios: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
No major evidence gap flagged.
6 total sources · 33% primary
At least one cited source is dated 2026.
Newcomer: Bessemer India returns revealed (Mar 2026)
Maintain monthly source check; escalate on fund close, DRHP, OFS, block sale or senior-partner change.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
80+ India companies all-time; ~40 currently listed on the firm's India page. 12 tracked below.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Sarvam AI | AI | 2026 | Series B (led) | Unicorn | ▲ | $234M first close at $1.5bn: largest pure-play Indian AI round; Nvidia/Amazon reported in |
| Perfios | Fintech | 2017 | Series A | Unicorn | ▲ | Holds >26%; IPO prep ~$500M at ~$2bn; FY25 profit ₹104 Cr |
| Urban Company | Consumer & Commerce | 2015 | Early | Public | ▲ | Sold ₹173 Cr in OFS at 14.4x; listed +57.5% |
| NephroPlus | Healthcare | 2011 | Early | Public | ▲ | Listed Dec 2025; Bessemer is promoter: did not sell in OFS |
| Swiggy | Consumer & Commerce | 2016 | Series C | Public | ▲ | Claimed as portfolio IPO; absent from OFS list: residual position unclear (U) |
| Livspace | Consumer & Commerce | 2018 | Growth | Unicorn | → | Home interiors |
| PharmEasy | Healthcare | 2018 | Series C | Unicorn | ▼ | Distressed-recap history |
| TransBnk | Fintech | 2025 | Series B (led) | Private | ▲ | $25M: transaction banking infra |
| Seekho | Consumer & Commerce | 2025 | Series B (led) | Private | ▲ | $28M: vernacular learning subscriptions |
| Pluro | Healthcare | 2025 | Series A (led) | Private | · | ₹125 Cr at ₹1,000 Cr: fertility/IVF |
| Mitigata | AI | 2026 | Series B (led) | Private | · | $15M: AI-native cyber insurance |
| Easebuzz | Fintech | 2025 | Series A (led) | Private | ▲ | $30M: payments platform |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
Fund II deploys lead cheques almost exclusively: six led rounds in fifteen months across fintech infra, health services and AI, and then broke its own stage discipline for Sarvam. That one cheque converts Bessemer from an early-stage specialist into the sovereign-AI thesis's institutional anchor.
$1.5bn post; 'India needs a complete sovereign AI stack'
Cyber insurance
Realisation · are LPs getting paid?
Medi Assist is the exit case study the industry should teach: IPO the position, then sell down in two clean blocks to institutional buyers over 18 months, ~₹1,158 Cr realised, no drama. Combined with Urban Company's 14.4x OFS, the 2024-26 window turned Bessemer's leaked 'cash returner, lagging IRR' profile into live distributions.
₹173 Cr OFS at a reported 14.4x on the tranche; +57.5% debut.
Sold the entire remaining 15.67% for ₹577.8 Cr to Citi, Goldman, Morgan Stanley, Kotak MF et al.: completing a staged exit (~₹1,158 Cr post-IPO) of a 10+ year position.
13.5% for ₹580 Cr at ₹611.70 average (29.22% → 15.72%).
Listed; Bessemer held as promoter: no OFS sale.
On $774M committed 2006-2024, + $1.6bn residual marks (as of Mar 2024)
Same leak: slow compounding; Fund I (2021) had 'no breakout yet' by mid-2024
Full staged realisation Aug 2025
$220M → $350M within four years: LP re-up evidence
The leaked dataset makes Bessemer the most performance-transparent firm in the cohort after Accel: near-1x returned with a 2x+ residual marked: honest, unspectacular, real. GW read: the Sarvam lead is the franchise's variance bet; if sovereign AI works, the IRR criticism dies with it. E.
What they're doing
Lead early rounds in unglamorous infrastructure: transaction banking, payments, credit data, dialysis, TPAs: cash-generative India.
Sovereign AI stack thesis: Sarvam lead + Mitigata + Protectt.ai: own the AI-security-sovereignty triangle.
Staged block-sale realisation discipline (Medi Assist template).
Build the bench for the thesis: senior AI/cyber partner hire (Mitra), COO, VP promotions: hiring ahead of deployment.
What can break
The Sarvam cheque is a stage-and-size departure: growth pricing in frontier AI is exactly where its early-stage discipline never had to operate.
Fund I (2021 vintage) still lacks a breakout per the leaked data: the step-up Fund II was raised on the old global-era record.
Perfios IPO timing: >26% of a ~$2bn listing is the book's biggest single swing after Sarvam.
Sarvam Series B final size and formal lead designation ($234M first close of ~$300M; press conflicting).
Perfios IPO (~$500M at ~$2bn target): the book's biggest pending realisation.
Swiggy residual position: absent from OFS lists; size unclear.
Fund I breakout: whether any 2021-vintage position re-rates by end-2026.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
The leak did Bessemer a favour: near-1x returned with $1.6bn still marked is a profile most India managers claim and can't show. Underwrite Fund II on whether the 2021 vintage finds its breakout, and treat the Sarvam position as a call option you're paying growth prices for.
Bessemer's lead-cheque velocity in fintech infra and health services is quietly taking the 'boring but bankable' Series A/B lane. And by anchoring Sarvam, it now owns the sovereign-AI cap table everyone else will pay up to enter.
Watch Perfios (~$2bn IPO prep) as the fintech-infra benchmark print, and the Sarvam cap table (Bessemer, Nvidia, Amazon, HCLTech) as the definitive map of who owns India's foundational-AI layer.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.